Biotech · Private company · Haddonfield, NJ, US
Linnaeus Therapeutics, Inc.
Track this companyFree. Adds Linnaeus Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials22 recruiting or active
Pipeline programs8From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline8
- Chemotherapy (dacarbazine or temozolomide)Phase 3 · Melanoma (Skin Cancer)ClinicalTrials.gov · fetched Nov 12, 2026
- Immunotherapy (ipilimumab and nivolumab)Phase 3 · Melanoma (Skin Cancer)ClinicalTrials.gov · fetched Nov 12, 2026
- Immunotherapy (nivolumab and relatlimab)Phase 3 · Melanoma (Skin Cancer)ClinicalTrials.gov · fetched Nov 12, 2026
- Immunotherapy (Pembrolizumab)Phase 3 · Melanoma (Skin Cancer)ClinicalTrials.gov · fetched Nov 12, 2026
- LNS8801Phase 3 · Melanoma (Skin Cancer)ClinicalTrials.gov · fetched Nov 12, 2026
- PembrolizumabPhase 3 · Melanoma (Skin Cancer)ClinicalTrials.gov · fetched Nov 12, 2026
- LNS8801 -Small molecule, orally bioavailable, selective agonist of GPERPhase 2 · Solid Tumor, AdultClinicalTrials.gov · fetched Nov 12, 2026
- Pembrolizumab - anti-PD-1 antibodyPhase 2 · Solid Tumor, AdultClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials2
- A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory MelanomaPHASE2_PHASE3 · RECRUITING · started Aug 6, 2025ClinicalTrials.gov NCT06624644 · fetched Nov 12, 2026
- Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With PembrolizumabPHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started Oct 21, 2019ClinicalTrials.gov NCT04130516 · fetched Nov 12, 2026
NIH awards2
- Development of LNS8801 for cutaneous melanoma patients who cannot tolerate immunotherapyFiscal year 2026 · $1MNIH RePORTER 5R44CA297994-02 · fetched Nov 12, 2026
- Development of LNS8801 for cutaneous melanoma patients who cannot tolerate immunotherapyFiscal year 2025 · $1MNIH RePORTER 1R44CA297994-01 · fetched Nov 12, 2026